Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galectovid is a proprietary medical food formulated as a peppermint-flavored chewable tablet designed to support the body’s natural defenses by targeting and reducing the activity of Galectin-1 and Galectin-3 proteins. These galectin proteins are implicated in chronic inflammation, immune system regulation, and viral infections. By acting as a galectin antagonist—specifically inhibiting both Galectin-1 and Galectin-3—Galectovid aims to limit viral invasion, reduce inflammation, and enhance immune response. The product is intended for dietary management of conditions associated with overexpression of these galectins, including chronic inflammatory states and persistent viral infections such as Long COVID. It is not classified as a pharmaceutical drug but rather as a medical food to be used under physician supervision[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Galectovid.